LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Bose, Chirantan"
  2. AU="Bell, J. F."
  3. AU="Creavin, Samuel T"
  4. AU="Boonprasong, Sakarin"
  5. AU="Sara Carvalho"
  6. AU="Xia, Zhenqing"

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.

    Page, Raymond / Patil, Darshana / Akolkar, Dadasaheb / Murthy, Sudha S / Bendale, Kiran / Patil, Revati / Fulmali, Pradeep / Fulmali, Pooja / Adhav, Archana / Puranik, Sneha / Apurwa, Sachin / Datta, Vineet / Bose, Chirantan / Schuster, Stefan / John, Jinumary / Srinivasan, Ajay / Datar, Rajan

    PloS one

    2022  Volume 17, Issue 6, Page(s) e0270139

    Abstract: Biomarker directed selection of targeted anti-neoplastic agents such as immune checkpoint inhibitors, small molecule inhibitors and monoclonal antibodies form an important aspect of cancer treatment. Immunohistochemistry (IHC) analysis of the tumor ... ...

    Abstract Biomarker directed selection of targeted anti-neoplastic agents such as immune checkpoint inhibitors, small molecule inhibitors and monoclonal antibodies form an important aspect of cancer treatment. Immunohistochemistry (IHC) analysis of the tumor tissue is the method of choice to evaluate the presence of these biomarkers. However, a significant barrier to biomarker testing on tissue is the availability of an adequate amount of tissue and need for repetitive sampling due to tumor evolution. Also, tumor tissue testing is not immune to inter- and intra-tumor heterogeneity. We describe the analytical and clinical validation of a Circulating Tumor Cell (CTC) assay to accurately assess the presence of PD-L1 22C3 and PD-L1 28.8, ER, PR and HER2, from patients with solid tumors to guide the choice of suitable targeted therapies. Analytically, the test has high sensitivity, specificity, linearity and precision. Based on a blinded case control study, the clinical sensitivity and specificity for PD-L1 (22C3 and 28.8) was determined to be 90% and 100% respectively. The clinical sensitivity and specificity was 83% and 89% for ER; 80% and 94% for PR; 63% and 89% for HER2 (by ICC); and 100% and 92% for HER2 (by FISH), respectively. The performance characteristics of the test support its suitability and adaptability for routine clinical use.
    MeSH term(s) B7-H1 Antigen ; Biomarkers, Tumor/analysis ; Carcinoma, Non-Small-Cell Lung/pathology ; Case-Control Studies ; Humans ; Lung Neoplasms/pathology ; Neoplastic Cells, Circulating
    Chemical Substances B7-H1 Antigen ; Biomarkers, Tumor
    Language English
    Publishing date 2022-06-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0270139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma.

    Limaye, Sewanti / Patil, Darshana / Akolkar, Dadasaheb / Srivastava, Navin / Patil, Revati / Apurwa, Sachin / Patil, Sanket / John, Jinumary / Gosavi, Rahul / Nesargikar, Prabhu / Kumar, Prashant / Datta, Vineet / Bose, Chirantan / Raazi, Zarrine / Srinivasan, Ajay / Datar, Rajan

    Clinical case reports

    2021  Volume 9, Issue 11, Page(s) e04986

    Abstract: Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric ... ...

    Abstract Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.
    Language English
    Publishing date 2021-11-07
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.4986
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top